A better understanding of the molecular events that regulate Hdm2 in nonpathological versus oncogenic contexts might contribute to the development of new anti-Hdm2 drugs that are more efficient and less deleterious to healthy tissues, and thus limiting potential side effects of these promising anti-cancer therapies. Here, MDM2 is linked to cancer.